Literature DB >> 1644073

Characteristics of the 'metabolic syndrome X' in a cardiovascular low risk population in Crete.

A D Koutis1, C D Lionis, A Isacsson, A Jakobsson, M Fioretos, L H Lindholm.   

Abstract

We have studied hypertension, obesity, diabetes and hypercholesterolaemia in those aged 45-79 years in the Cretan low risk population of Spili (n = 249; attendance 82%) to see if these conditions interacted in the same way as previously described for high risk populations. Hypertension, diabetes, obesity, and hypercholesterolaemia were found to be at least as prevalent in Spili as in Sweden. Furthermore, the previously described 'Metabolic Syndrome X', with insulin resistance and hyperinsulinaemia as a common denominator also seemed to exist in the Spili population where patients with these conditions had higher insulin and C-peptide levels than normals. Our finding should be viewed against the low prevalence of past myocardial infarction in Cretan men from Spili reported by us and confirming the results of the Seven Countries Study.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1644073     DOI: 10.1093/oxfordjournals.eurheartj.a060284

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  2 in total

1.  Health care access and prevalence of the metabolic syndrome among elders living in high-altitude areas of the Mediterranean islands: the MEDIS study.

Authors:  Stefanos Tyrovolas; Christos Chalkias; Marianthi Morena; Ioanna Tsiligianni; Akis Zeimbekis; Efthimios Gotsis; George Metallinos; Vassiliki Bountziouka; Evangelos Polychronopoulos; Christos Lionis; Demosthenes Panagiotakos
Journal:  Rev Diabet Stud       Date:  2012-02-10

2.  Risk factors for ischaemic heart disease in a Cretan rural population: a twelve year follow-up study.

Authors:  Ioannis K Karalis; Athanasios K Alegakis; Antonios G Kafatos; Antonios D Koutis; Panos E Vardas; Christos D Lionis
Journal:  BMC Public Health       Date:  2007-12-18       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.